TNSN96007A1 - Purine - 6 - ones 2,9 - disubstituees - Google Patents

Purine - 6 - ones 2,9 - disubstituees

Info

Publication number
TNSN96007A1
TNSN96007A1 TNTNSN96007A TNSN96007A TNSN96007A1 TN SN96007 A1 TNSN96007 A1 TN SN96007A1 TN TNSN96007 A TNTNSN96007 A TN TNSN96007A TN SN96007 A TNSN96007 A TN SN96007A TN SN96007 A1 TNSN96007 A1 TN SN96007A1
Authority
TN
Tunisia
Prior art keywords
purine
disubstituted
ones
cyclisting
acyling
Prior art date
Application number
TNTNSN96007A
Other languages
English (en)
Inventor
Ulrich Niewohner Dr
Erwin Bischoff Dr
Helmuth Schutz Dr
Elisabeth Perzborn Dr
Matthias Schramm Dr
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of TNSN96007A1 publication Critical patent/TNSN96007A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

ON PREPARE DES PURINE - 6 - ONES 2,9 - DISUBSTITUEES EN ACYLANT, DANS UNE PREMIERE ETAPE, DES AMINOIMIDAZOLES CONVENABLEMENT SUBSTITUEES, PUIS EN CYCLISANT LE PRODUIT POUR OBTENIR LA PURINE. LES NOUVELLES PURINE - 6 - ONES 2,9 - DISUBSTITUEES PEUVENT ETRE UTILISEES COMME PRINCIPES ACTIFS DANS DES MEDICAMENTS, EN PARTICULIER POUR LE TRAITEMENT DES INFLAMMATIONS, DES MALADIES THROMBOEMBOLIQUES ET CARDIO-VASCULAIRES, ET DES MALADIES DU SYSTEME UROGENITAL.
TNTNSN96007A 1995-01-19 1996-01-17 Purine - 6 - ones 2,9 - disubstituees TNSN96007A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501482A DE19501482A1 (de) 1995-01-19 1995-01-19 2,9-disubstituierte Purin-6-one

Publications (1)

Publication Number Publication Date
TNSN96007A1 true TNSN96007A1 (fr) 2005-03-15

Family

ID=7751830

Family Applications (2)

Application Number Title Priority Date Filing Date
TNTNSN96007A TNSN96007A1 (fr) 1995-01-19 1996-01-17 Purine - 6 - ones 2,9 - disubstituees
TNTNSN96006A TNSN96006A1 (fr) 1995-01-19 1996-01-17 Quinazolinones 2,8-disubstituees

Family Applications After (1)

Application Number Title Priority Date Filing Date
TNTNSN96006A TNSN96006A1 (fr) 1995-01-19 1996-01-17 Quinazolinones 2,8-disubstituees

Country Status (31)

Country Link
US (1) US5861404A (fr)
EP (1) EP0722944A1 (fr)
JP (1) JPH08231545A (fr)
KR (1) KR960029334A (fr)
CN (1) CN1135485A (fr)
AR (1) AR002953A1 (fr)
AU (1) AU4097996A (fr)
BG (1) BG61728B1 (fr)
BR (1) BR9600147A (fr)
CA (1) CA2167353A1 (fr)
CO (1) CO4700523A1 (fr)
CZ (1) CZ16696A3 (fr)
DE (1) DE19501482A1 (fr)
EE (1) EE9600018A (fr)
FI (1) FI960225A (fr)
HR (1) HRP960007A2 (fr)
HU (1) HUP9600106A3 (fr)
IL (1) IL116769A (fr)
MA (1) MA23778A1 (fr)
NO (1) NO960223L (fr)
NZ (1) NZ280830A (fr)
PE (1) PE64996A1 (fr)
PL (1) PL312354A1 (fr)
SG (1) SG50401A1 (fr)
SK (1) SK8096A3 (fr)
SV (1) SV1996000006A (fr)
TN (2) TNSN96007A1 (fr)
TR (1) TR199600028A2 (fr)
TW (1) TW314519B (fr)
YU (1) YU1396A (fr)
ZA (1) ZA96398B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529102A1 (de) * 1995-08-08 1997-02-13 Kummer Horst Dieter Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6310070B1 (en) * 1997-07-15 2001-10-30 Japan Energy Corporation Purine derivatives and medicinal use thereof
WO1999024432A1 (fr) * 1997-11-12 1999-05-20 Mitsubishi Chemical Corporation Derives de purine et medicament les renfermant en tant qu'ingredient actif
EP1054012B1 (fr) * 1998-01-05 2003-06-11 Eisai Co., Ltd. Derives de purine et antagonistes du recepteur a2 d'adenosine utiles comme moyens de prevention/traitement du diabete
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6660745B1 (en) * 1999-05-11 2003-12-09 Mitsubishi Chemical Corporation Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
NZ524572A (en) * 2000-09-06 2004-08-27 Tanabe Seiyaku Co Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
US7927623B2 (en) * 2001-02-15 2011-04-19 Mitsubishi Tanabe Pharma Corporation Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CN102742513A (zh) * 2012-07-17 2012-10-24 南京熊猫机电制造有限公司 一种喂食栏装置
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
BG61728B1 (bg) 1998-04-30
NO960223L (no) 1996-07-22
TNSN96006A1 (fr) 2005-03-15
FI960225A (fi) 1996-07-20
PE64996A1 (es) 1997-03-09
TR199600028A2 (tr) 1996-08-21
SV1996000006A (es) 1996-10-29
CN1135485A (zh) 1996-11-13
CO4700523A1 (es) 1998-12-29
NO960223D0 (no) 1996-01-18
FI960225A0 (fi) 1996-01-17
NZ280830A (en) 1998-04-27
ZA96398B (en) 1996-08-28
EP0722944A1 (fr) 1996-07-24
AU4097996A (en) 1996-07-25
CA2167353A1 (fr) 1996-07-20
HRP960007A2 (en) 1998-02-28
HUP9600106A3 (en) 1998-04-28
MA23778A1 (fr) 1996-10-01
TW314519B (fr) 1997-09-01
AR002953A1 (es) 1998-05-27
US5861404A (en) 1999-01-19
SK8096A3 (en) 1996-08-07
PL312354A1 (en) 1996-07-22
EE9600018A (et) 1996-08-15
CZ16696A3 (en) 1996-08-14
KR960029334A (ko) 1996-08-17
IL116769A (en) 1998-12-06
BG100292A (bg) 1996-07-31
IL116769A0 (en) 1996-05-14
HU9600106D0 (en) 1996-03-28
YU1396A (sh) 1999-03-04
HUP9600106A2 (en) 1997-05-28
DE19501482A1 (de) 1996-07-25
BR9600147A (pt) 1998-01-06
JPH08231545A (ja) 1996-09-10
SG50401A1 (en) 1998-07-20

Similar Documents

Publication Publication Date Title
TNSN96007A1 (fr) Purine - 6 - ones 2,9 - disubstituees
TNSN97048A1 (fr) Pyridines 2 - aryl - substituees.
CA2180816A1 (fr) 6-dimethylaminomethyl-1-phenylcyclohexanes, principes actifs en pharmacie
HUT37418A (en) Process for producing new 2,2'-imino-bis/ethanol/ derivatives and pharmaceutical compositions sontaining them as active agents
NO20011539L (no) Hydrokolloid sukkervare
ES2153498T3 (es) Proceso para preparar formas de dosificacion farmaceutica solidas.
ATE210965T1 (de) Zusammensetzungen zur topischen abgabe von aktiven wirkstoffen
CA2380068A1 (fr) Compositions de film a base de pullulane
CA2190882A1 (fr) Preparation de compositions de principe actif sous forme de solution solide dudit principe actif dans une matrice polymere et preparations de principe actif obtenues a l'aide dudit procede
DE59510626D1 (de) Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
NO965388D0 (no) Fremgangsmåte og apparat for fremstilling av vasket opplöselige doseenheter og produkter derav
ATE217525T1 (de) Tiagabin enthaltende spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3782621D1 (de) Imidazol-derivate, verfahren zu ihrer herstellung, pharmazeutische zubereitungen, welche diese enthalten, verwendung dieser zur herstellung therapeutisch wirksamer arzneimittel und zwischenprodukte, welche beim herstellungsverfahren entstehen.
ATE259369T1 (de) Neue geranylgeranylderivate, verfahren zu deren herstellung und entsprechende pharmazeutische zusammensetzungen
GR3020575T3 (en) New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
IT8322648A0 (it) Derivati dell'acido 4-fenil4-osso-buten 2-oico, loro procedimento di preparazione e loro applicazione come prodotti medicinali.
DE3770726D1 (de) Decahydrochinolinderivate, verfahren zu ihrer herstellung und zwischenprodukte davon, ihre verwendung als arzneimittel und ihre pharmazeutischen zusammensetzungen.
HUT47124A (en) Process for producing pharmaceutical compositions comprising organic platinum complex as active ingredient and the active ingredients
HUT54166A (en) Process for producing 1,1-dioxocefem-4-carbothiol acid derivatives and pharmaceutical compositions comprising same as active ingredient
ZA968762B (en) Derivatives of acid pyrazoles, their preparation process, their use as medicaments, their new use and the pharmaceutical compositions containing them.
EA199900998A1 (ru) Полутвердый фармацевтический препарат, содержащий декскетопрофентрометамол
FR2740991B1 (fr) Nouveaux extraits de plantes, leur procede de fabrication et leur utilisation dans les produits cosmetiques
HUT56353A (en) Herbicidal compositions comprising salicilic acid derivatives and process for producing the active ingredients
FR2622800B1 (fr) Procede de preparation d'un produit de lutte contre des affections virales en particulier des affections virales cutaneo-muqueuses,compositions pharmaceutiques et medicaments obtenus a partir de ce procede
BE862053A (fr) Peptides contenant de la phenylglycine utiles comme medicaments, procede pour leur preparation et compositions pharmaceutiques en contenant